HistoSonics is developing a non-invasive sonic beam therapy platform and procedure to liquify and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The company’s new platform delivers personalized, tissue specific treatments with precision and control, and without the undesirable side effects of many of today’s interventional and surgical modalities.

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations. The company's cloud-based platform and expert services help healthcare systems and providers manage and unify their data to realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future where every healthcare decision is data-informed.

Ipsen is a global biopharmaceutical company dedicated to developing and commercializing innovative medicines in specialized areas like oncology, rare disease, and neuroscience, with a primary focus on improving the lives of patients worldwide through research and specialty care. Ipsen’s therapeutic areas include oncology (especially hard-to-treat cancers), rare diseases, and neuroscience.

Natera is a global leader in cell-free DNA testing, dedicated to advancing precision oncology. Its Signatera™ test is an ultrasensitive, personalized circulating tumor DNA (ctDNA) assay designed to detect molecular residual disease (MRD), monitor recurrence, and assess treatment response across tumor types. Signatera is the most extensively validated, widely used, and broadly reimbursed MRD assay, incorporated into more than 40 prospective studies.

AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.

Artios, a gold sponsor of the Canopy 2025 Learning Session, is pioneering approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of DDR drug developers. The company has very promising clinical data in GI indications with their ATR inhibitor, ART0380 (alnodesertib), and are looking forward to partnering with cooperative groups like Canopy to continue to drive their program forward.

MyCareGorithm develops tools to transform the consultation encounter between a cancer patient and a cancer specialist with a personalized educational experience.

We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative targeted therapies for patients living with RAS-addicted ancer. At Revolution Medicines, we believe in challenging the status quo to find new therapeutic approaches to some of the toughest cancers. With our first wave of RAS(ON) inhibitors, we are pioneering a new way of targeting the RAS cancer drivers of disease, and we have the potential to change the treatment paradigm in these cancers where there is a significant unmet medical need.

At Foundation Medicine, our mission is to transform lives in cancer and beyond. We strive to provide multi-modal precision diagnostic solutions to transform cancer care throughout a patient’s experience, from pre-diagnosis to ongoing management and monitoring. Leveraging our vast knowledge of precision medicine, we partner with biopharmaceutical companies to accelerate the development of new personalized therapies in cancer and in a range of other diseases.

Artidis® AG is a pioneering clinical stage health technology company that aims to set the gold standard in tissue analysis and therapy optimization. By combining its nanotechnology platform for rapid tissue analysis with a holistic data solution, Artidis® accelerates drug discovery, tissue engineering, and personalized treatment. Artidis® focuses its research and development efforts on solid tumors to enhance responses to chemotherapy, immunotherapy, and cell therapies, driving precision in cancer care.